Alvarius is an Irish biopharmaceutical company researching and developing unique therapies to target addiction through the pioneering use of 5-MeO-DMT medicines.
Alvarius
Alvarius raised $3.28 million in an early-stage venture capital round of funding in January 2021.
The company is funded, in part by Re:Mind Capital (Christian Angermayer).
“Alvarius aims to help patients overcome addictive substance-related behaviours with ground-breaking pharmaceutical solutions combined with tailored therapy. Together with our collaboration partners in University College Dublin, we are utilising the latest scientific methods to unlock the potential of psychedelics and associated therapy in treating addiction and other mental illnesses, and exploring the many associated benefits of these underused, misunderstood, and often stigmatised substances.”
Key Staff
- James Linder – Co-Founder
- David Nutt – Director
News
- Psychedelics start-up Alvarius goes on fundraising trip (The Times, January 2021)
Activities
B2B
B2C
Pharmaceutical
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates